Sexual Dysfunction with Aromatase Inhibitor Therapy: An Underestimated Problem?

Swedish study shows AI use is associated with low sexual desire, inadequate vaginal lubrication, and sexual dissatisfaction.

Aromatase inhibitor (AI) therapy has become a standard adjuvant endocrine treatment for postmenopausal women with hormone receptor–positive tumors; however, its impact on sexuality remains to be investigated. In this cross-sectional study, Swedish investigators enrolled 82 women with receptor-positive breast cancer and 105 age-matched women without breast cancer (mean age of all participants at entry, 62). Sexual function was assessed in four groups: women with breast cancer who were using tamoxifen or AIs, and women without breast cancer who were or were not using vaginal or systemic estrogen.

Overall, 60% to 68% of participants reported being sexually active. Distressing low sexual desire was nonsignificantly more prevalent in AI users (21…

Reviewing Author

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Sexual Dysfunction with Aromatase Inhibitor Therapy: An Underestimated Problem?

Topics

Reviewing Author